Metal nanocomposite Cu2O@TPPO, and preparation method and application thereof
Cu2O@TPPO nanoparticles prepared by simplifying the synthesis process solve the problem of easy oxidation and aggregation of copper-based nanocatalysts, and achieve efficient and stable anti-tumor therapeutic effects.
Patent Information
- Application Number
- CN202611081262.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-21
- Publication Date
- 2026-11-10
AI Technical Summary
Existing cuprous nanocatalysts are prone to oxidation and aggregation, which reduces their ability to catalyze the generation of reactive oxygen species (ROS) and limits their application in anti-tumor therapy.
Using Stryker reagent as a copper precursor, highly active and stable cuprous oxide (Cu2O) nanoparticles Cu2O@TPPO were prepared by spontaneous surface hydrolysis and in-situ oxidation with triphenylphosphine oxide (TPPO) ligands. This simplified the synthesis process and promoted the formation of oxygen vacancies.
Cu2O@TPPO nanoparticles exhibit good catalytic activity and stability, demonstrating significant antitumor activity and biosafety both in vivo and in vitro. They can induce tumor cell apoptosis and copper death, effectively inhibiting tumor growth.
Smart Images

Figure CN123059080A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, and in particular relates to a metal nanocomposite Cu2O@TPPO, its preparation method, and its application in antitumor drugs. Background Technology
[0002] Cancer is one of the leading causes of death worldwide. Despite significant progress in cancer diagnosis and treatment in recent years, traditional treatments (such as surgery, radiotherapy, and chemotherapy) still have unavoidable toxic side effects on normal tissues, and patients are highly susceptible to developing resistance to various anti-tumor drugs. Therefore, developing novel, highly effective, and low-toxicity therapeutic drugs has become a key focus of current research. Nanomedicines have attracted considerable attention in the field of cancer treatment due to their advantages such as precise targeting, optimized performance, synergistic effects, and lower toxicity.
[0003] Copper, an essential trace element for life, plays a crucial role in the regulation of various biological processes, including angiogenesis, cell proliferation, energy metabolism, and redox homeostasis. In recent years, the catalytic role of copper ions in chemokinetic therapy has attracted widespread attention from researchers. Copper ions (Cu...) + / Cu 2+ Copper ions can efficiently catalyze the decomposition of hydrogen peroxide (H2O2) into reactive oxygen species (ROS) through a Fenton-like reaction, thereby exerting an anti-tumor effect. Furthermore, the accumulation of copper ions in tumor cells can induce cell death through various mechanisms. For example, excessive copper ions can bind to thiol groups in mitochondria, interfering with mitochondrial function; simultaneously, copper ions can bind to lipoylated proteins, leading to their abnormal aggregation and triggering a novel form of cell death—copper death.
[0004] In recent years, various copper-based nanoparticles have been applied in in vivo and in vitro studies. Besides copper metal-organic frameworks (Cu-MOFs) and copper oxide-based materials, cuprous oxide nanoparticles have also shown significant anticancer potential. This is mainly attributed to Cu… + Compared to Cu 2+ The lower redox potential enables cuprous nanocatalysts to exhibit stronger catalytic performance.
[12] However, cuprous nanocatalysts are prone to oxidation and aggregation, which significantly reduces their ability to catalyze the generation of reactive oxygen species (ROS), greatly limiting their clinical applications. Therefore, designing a protective cuprous nanocatalyst with stable active sites to enhance the efficacy of chemokinetic therapy (CDT) has become a current research focus. Summary of the Invention
[0005] To address the problems existing in the prior art, this invention provides a metal nanocomposite Cu2O@TPPO, its preparation method, and its application in antitumor drugs.
[0006] The preparation method of the Cu2O@TPPO nanocomposite described in this invention is as follows: using commercial Stryker reagent The reagent can be used directly as a copper precursor without further purification. It is placed in a glass container and left to stand at ambient pressure for 24 hours to allow spontaneous surface hydrolysis and in-situ oxidation of the triphenylphosphine oxide (TPPO) ligand. The entire process requires no additional solvents, ligand additives, heating, or cooling. After the reaction, the resulting Cu2O@TPPO nanoparticles are dispersed in dichloromethane (DCM) and purified by centrifugation at 8000 rpm for 10 minutes. The resulting precipitate is washed 3-5 times with DCM to thoroughly remove residual unreacted Stryker reagent and free phosphine byproducts. The purified Cu2O@TPPO nanoparticles are then naturally dried under vacuum for 48 hours and stored in a dry, light-proof container for subsequent characterization and performance testing.
[0007] The application of the metal nanocomposite Cu2O@TPPO described in this invention in the preparation of antitumor drugs.
[0008] This invention proposes an innovative strategy: using Stryker's reagent as a molecular precursor to synthesize highly active and stable cuprous oxide (Cu₂O) nanoparticles – Cu₂O@TPPO. Stryker's reagent, a copper hydride complex, is widely used in organic reduction reactions and serves as an ideal precursor for the controlled synthesis of nanoparticles, thus providing a new pathway for preparing high-performance cuprous oxide nanoparticles. Under oxidizing conditions, the triphenylphosphine ligand in this reagent is oxidized to triphenylphosphine oxide, accompanied by a transformation from an octahedral Cu₆ structure to a bitetrahedral structure. Notably, the oxidation of the triphenylphosphine (PPh₃) ligand in air plays a crucial role in this transformation, with the resulting triphenylphosphine oxide (O=PPh₃) promoting the formation of oxygen vacancies in the Cu₂O nanoparticles. Furthermore, unlike previously reported oxidation of triphenylphosphine (PPh₃) requiring high temperatures or photocatalysis, PPh₃ can be oxidized at room temperature in the presence of monovalent copper. This discovery not only simplifies the Cu₂O synthesis process but also provides new insights for developing highly efficient nanocatalysts. Experimental results also confirmed that this novel nanomedicine contains abundant oxygen vacancies and a high proportion of monovalent copper ions, exhibiting good catalytic activity and stability. Furthermore, it demonstrates good antitumor activity and biosafety both in vivo and in vitro, showcasing its potential as a novel nanotherapeutic agent. Attached Figure Description
[0009] Figure 1 Preparation process of copper oxide@TPPO.
[0010] Figure 2 HRTEM image of Cu2O@TPPO nanoparticles.
[0011] Figure 3 Elemental composition of Cu2O@TPPO nanoparticles (scale bar = 500 nm).
[0012] Figure 4 Particle size (a) and zeta potential (b) of Cu2O@TPPO nanoparticles.
[0013] Figure 5 Chemical valence state of copper ions on the surface of Cu2O@TPPO nanoparticles (a), and analysis of the chemical valence state of copper ions inside (b).
[0014] Figure 6 Deconvolution spectrum of Cu2O@TPPO nanoparticles P 2p XPS (a), deconvolution spectrum of O 1s XPS (b), FTIR spectrum (c).
[0015] Figure 7 ESR spectrum of Cu2O@TPPO nanoparticles (a), nitrogen adsorption-desorption curve and pore size distribution (b), nitrogen adsorption-desorption curve and pore size distribution of commercial Cu2O (c), BET data analysis chart (d).
[0016] Figure 8 Analysis of the reaction products of Cu2O@TPPO and H2O2: (a) ·OH, (b) ·O2-.
[0017] Figure 9 The intracellular copper ion content after co-incubation of Cu2O@TPPO with cells (n=3).
[0018] Figure 10 Cu2O@TPPO exhibits tumor cell killing activity. (a) Image under an inverted fluorescence microscope (scale bar = 50 μm) and (b) Flow cytometry results of Cu2O@TPPO and A549 cells after co-incubation with Calcein-AM / PI staining.
[0019] Figure 11 Killing effect of Cu2O@TPPO on (a) MCF-7 cells and (b) A549 cells (n=5).
[0020] Figure 12 Anti-colony formation ability of Cu2O@TPPO (n=3) Figure 13(a) Image of intracellular reactive oxygen species (ROS) after co-incubation of Cu2O@TPPO with cells under an inverted fluorescence microscope (b) Flow cytometry results (n=4, scale bar=100 μm).
[0021] Figure 14 (a) Image of mitochondrial ROS levels in cells after co-incubation with Cu2O@TPPO under an inverted fluorescence microscope (b) Flow cytometry results (n=3, scale bar=100 μm).
[0022] Figure 15 (a) Image of mitochondrial membrane potential level of cells after co-incubation with Cu2O@TPPO under an inverted fluorescence microscope (b) Flow cytometry results (scale bar = 50 μm).
[0023] Figure 16 Cu2O@TPPO can induce tumor cell apoptosis. (a) shows the flow cytometry results of apoptosis-related detection after co-incubation of Cu2O@TPPO with cells. (b) shows the expression levels of apoptosis-related proteins detected by Western blot. (c) shows the quantitative analysis of protein expression levels.
[0024] Figure 17 Cu2O@TPPO can induce cell cycle arrest in tumor cells. (a) Flow cytometry results of cell cycle analysis after co-incubation of Cu2O@TPPO with cells. (b) Western blot analysis of apoptosis-related protein expression levels. (c) Quantitative analysis of protein expression levels.
[0025] Figure 18 Cu2O@TPPO can induce copper death in tumor cells. (a) Schematic diagram of the mechanism of copper death. (b) Results of intracellular GSH level detection. (c) Expression levels of apoptosis-related proteins detected by Western blot. (d, e) Quantitative analysis of protein expression levels. (f) Transmission electron microscopy image of cells (scale bar = 5 μm). Figure 19 Cu2O@TPPO exhibits in vivo tumor proliferation inhibitory activity. (a) Photographs of tumors in each group of nude mice; (b) Changes in tumor volume in mice; (c) Weight of tumor tissue in mice (n = 6).
[0026] Figure 20 Changes in protein expression levels in mouse tumor tissue (a) and (bf) plot of quantitative analysis of protein expression levels (n=3).
[0027] Figure 21 H&E staining of major organs in mice.
[0028] Figure 22Mouse blood biochemical indicators (a) T-BIL: total bilirubin (b) ALB: albumin (c) ALT: alanine aminotransferase (d) AST: aspartate aminotransferase (e) BUN: blood urea nitrogen (f) CR: creatinine (g) UA: uric acid detection results (n=6).
[0029] Figure 23 Weights of major organs in mice: (a) lung, (b) liver, (c) spleen, (d) heart, and (e) kidney (n=6). Detailed Implementation
[0030] The technical solution of the present invention will be further described below with reference to specific embodiments.
[0031] Preparation method of Cu2O@TPPO: Commercial Stryker reagent It can be used directly as a copper precursor without further purification. 50 mg of the reagent was placed in a glass container and allowed to stand for 24 hours under normal atmospheric pressure to allow spontaneous surface hydrolysis and in-situ oxidation of the triphenylphosphine oxide (TPPO) ligand. The entire process required no additional solvents, ligand additives, or heating or cooling. After the reaction, the resulting Cu₂O@TPPO nanoparticles were dispersed in dichloromethane (DCM) and purified by centrifugation at 8000 rpm for 10 minutes. The resulting precipitate was washed five times with DCM to thoroughly remove residual unreacted Stryker reagent and free phosphine byproducts. 30 mg of the purified Cu₂O@TPPO nanoparticles were then naturally dried under vacuum for 48 hours and stored in a dry, light-protected container for subsequent characterization and performance testing. The preparation process of copper oxide@TPPO is described in [link to relevant documentation]. Figure 1 . I. Elemental composition and physicochemical characterization of Cu2O@TPPO 1. Morphological and structural characterization of Cu2O@TPPO: The lattice structure of the Cu2O@TPPO nanoparticles was observed by HRTEM. The lattice fringes were clear, indicating good crystallinity and a lattice spacing of approximately 0.24 nm, corresponding to the 111 crystal plane. Figure 2 ).
[0032] 2. Elemental Composition of Cu2O@TPPO We systematically analyzed the elemental composition of Cu2O@TPPO using energy-dispersive X-ray spectroscopy (EDS). EDS results showed that C, O, P, and Cu were uniformly distributed in the material. Figure 3 This result confirms the successful oxidation of the Stryker reagent. Furthermore, the characteristic peaks of Cu, O, P, and C were clearly observed in the EDS spectrum, further verifying that the chemical composition of Cu₂O@TPPO is consistent with our expected structure.
[0033] 3. Size and Surface Charge Characteristics of Cu2O@TPPO We further characterized the size of Cu2O@TPPO nanoparticles using dynamic light scattering (DLS) technology. The results are as follows: Figure 4 As shown in figure a, the average diameter of the nanoparticles is approximately 25 nm. This diameter size allows the nanoparticles to possess excellent tumor tissue penetration ability and effectively avoid rapid clearance by the liver and kidneys, thereby prolonging their circulation time in the body. Our zeta potential level detection results indicate that the Cu2O@TPPO surface carries a greater positive charge ( Figure 4 b) This indicates that Cu2O@TPPO should have good dispersibility and stability.
[0034] 4. Analysis of elemental valence states and chemical bond formation of Cu2O@TPPO (1). Fine X-ray photoelectron spectroscopy (XPS) analysis of Cu 2p showed distinct characteristic peaks at binding energies of 932.7 eV and 952.5 eV, corresponding to the 2p3 / 2 and 2p1 / 2 energy levels of Cu+. Furthermore, a weak Cu2+ accompanying peak was observed in the spectrum, indicating that only a small amount of Cu exists on the Cu2O@TPPO surface. 2+ And Cu + It remains its primary chemical state ( Figure 5 a). Furthermore, within Cu2O@TPPO, Cu exists entirely in its unoxidized state (+1 valence). Figure 5 b). These results indicate that Cu2O@TPPO has a low degree of surface oxidation and its internal structure has good stability.
[0035] (2). XPS fine spectral analysis of P 2p and O 1s: Peak fitting of the P 2p XPS spectrum showed that it could be deconvolved into two characteristic peaks at 132.5 eV and 130.5 eV, corresponding to the CP bond and the P=O bond, respectively. Figure 6 a). Additionally, the O 1s XPS spectrum can also be deconvolved into two characteristic peaks at 532.5 eV and 530.7 eV, corresponding to the PO bond and the Cu-O bond, respectively. Figure 6 b). These results indicate that Ph3P=O is effectively bonded to the Cu2O surface via Cu-O bonds, which further verifies that the chemical structure of Cu2O@TPPO is consistent with our assumption.
[0036] (3). Fourier transform infrared (FTIR) spectroscopy analysis of Cu2O@TPPO revealed characteristic absorption peaks of the P=O bond at specific wavenumbers. Figure 6c). This result confirms that O=PPh3 was successfully functionalized on the Cu2O surface and further supports the reaction mechanism of Stryker reagent generating Cu2O@TPPO through oxidation intermediates.
[0037] 5. Oxygen vacancies and BET analysis of Cu2O@TPPO (1). Oxygen vacancy analysis of Cu2O@TPPO Oxygen vacancies on the surface of nanoparticles can significantly enhance the efficiency and selectivity of Fenton-like reactions. Taking Cu2O as an example, oxygen vacancies can promote the conversion of Cu+ to Cu2+, thereby accelerating the decomposition of H2O2. Furthermore, oxygen vacancies, as active sites, can adsorb and activate H2O2 molecules, while changes in the surrounding local electronic structure facilitate the breaking of the OO bonds in H2O2, thus improving the utilization rate of H2O2 and enhancing the efficiency of Fenton-like reactions. Through ESR experiments, we found that the Cu2O@TPPO surface is rich in oxygen vacancies (…). Figure 7 a) This phenomenon can be attributed to the oxidation of PPh3 ligands in air to form Ph3P=O, thereby promoting the formation of Cu2O nanoparticles with oxygen vacancies. This property offers potential advantages for its applications in catalysis and biomedicine.
[0038] (2). BET Experimental Analysis We conducted nitrogen adsorption-desorption experiments on Cu2O@TPPO and commercial Cu2O nanoparticles to determine the specific surface area, pore volume, and average pore size of the nanoparticles. The experimental results showed that the specific surface area of Cu2O@TPPO was 13.954 m² / g, which was higher than that of commercial Cu2O (4.119 m² / g). Furthermore, Cu2O@TPPO also had a higher pore volume and average pore size than commercial Cu2O nanoparticles. This indicates that Cu2O@TPPO contains more surface atoms and more catalytically active sites per unit mass.
[0039] 6. Types of Free Radicals Generated by Cu2O@TPPO Catalysis We used ESR to detect the types of free radicals generated by Cu2O@TPPO nanoparticles. Experimental results showed that after co-incubation of Cu2O@TPPO nanoparticles with hydrogen peroxide (H2O2), two types of free radicals were generated in the system: hydroxyl radicals (·OH) and... Figure 8 a) and superoxide radicals (·O2-) Figure 8 b). These results further confirm that Cu2O@TPPO nanoparticles have a highly efficient ability to generate reactive oxygen species (ROS) in catalytic reactions.
[0040] 7. Cu2O@TPPO Promotes Intracellular Copper Ion Accumulation. Before evaluating the in vitro antitumor activity of Cu2O@TPPO, we first determined whether it could promote the accumulation of copper ions in A549 cells. We used inductively coupled plasma optical emission spectrometry (ICP-OES) to quantitatively analyze the intracellular copper ion content after co-incubation with Cu2O@TPPO. The results showed that after co-incubation with 10 μg / mL Cu2O@TPPO for 24 h, the intracellular copper ion content was significantly increased compared with the control group (…). Figure 9 ).
[0041] 8. Cytotoxicity Evaluation of Cu2O@TPPO To assess the cytotoxicity of Cu2O@TPPO, we used the Calcein-AM / PI double staining method to detect cell viability after co-incubation with the drug. Calcein-AM labeled live cells and emitted green fluorescence, while propidium iodide (PI) specifically labeled dead cells and emitted red fluorescence. Fluorescence microscopy revealed that as the drug concentration increased, the red fluorescence in tumor cells significantly increased, while the green fluorescence gradually decreased. Figure 10 a).
[0042] To further quantify cytotoxicity, we performed a semi-quantitative analysis of cell viability using flow cytometry. The experimental results were consistent with those obtained under fluorescence microscopy. Figure 10 (b) As the drug concentration increases, the cell distribution shows a clear trend of shifting from the lower right quadrant (the area of living cells) to the upper left quadrant (the area of dead cells), indicating that the degree of cell damage gradually worsens with increasing drug concentration.
[0043] Next, we quantitatively evaluated the in vitro antitumor activity of Cu2O@TPPO using a CCK-8 assay. The results showed that Cu2O@TPPO exhibited significant cytotoxic effects against both human lung adenocarcinoma cells (A549) and breast cancer cells (MCF-7). Furthermore, the survival rates of both A549 and MCF-7 cells gradually decreased with increasing drug concentration. When the concentration reached 10 μg / mL, the survival rates of both cell types were below 50%. Figure 11 These results fully demonstrate that Cu2O@TPPO has significant tumor-suppressive activity against a variety of tumor cells, and this activity is concentration-dependent.
[0044] To further verify the tumor-suppressive activity of Cu2O@TPPO, we conducted a plate colony formation assay to verify the anti-colony-forming ability of Cu2O@TPPO. The results showed that, compared with the control group, the number of A549 cells treated with Cu2O@TPPO was significantly reduced, and this inhibitory effect exhibited a clear concentration-dependent effect. Figure 12This result demonstrates that Cu2O@TPPO can effectively inhibit the colony-forming ability of tumor cells, thus further confirming its potential application value in anti-tumor therapy.
[0045] 9. Cu2O@TPPO Promotes ROS Generation in A549 Cells. To investigate the effect of Cu2O@TPPO on intracellular ROS levels, we used the DCFH-DA fluorescent probe to evaluate the effect of drug intervention on intracellular ROS generation. DCFH-DA, a lipid-soluble compound, can freely cross the cell membrane and enter the cell, where it is converted into non-fluorescent DCFH under the catalysis of intracellular esterases. In the presence of ROS, DCFH is oxidized to DCF products with green fluorescence. Experimental results showed that the intensity of green fluorescence in A549 cells treated with Cu2O@TPPO was significantly enhanced, and the fluorescence intensity showed a clear concentration dependence, while the fluorescence signal in the control group cells was almost negligible. Figure 13 Semi-quantitative analysis by flow cytometry showed that at a concentration of 5.0 μg / mL, the fluorescence intensity of the cells was approximately 1.5 times that of the control group, while at a concentration of 10.0 μg / mL, the fluorescence intensity was almost 2.5 times that of the control group. Figure 13 These results fully demonstrate that Cu2O@TPPO can significantly induce the generation of ROS in A549 cells.
[0046] 10. Cu2O@TPPO Promotes ROS Production in A549 Cell Mitochondria. To further investigate the effect of Cu2O@TPPO on ROS levels in tumor cell mitochondria, we used the MitoSOX fluorescent probe for specific detection. MitoSOX is a cationic fluorescent probe that specifically targets mitochondria and reacts with ROS to generate red fluorescent products. Fluorescence microscopy results showed that, compared with control cells, the red fluorescence intensity of A549 cells pre-incubated with Cu2O@TPPO was significantly enhanced, and increased with increasing drug concentration. Figure 14 We further performed semi-quantitative detection of fluorescence intensity using flow cytometry. The results showed that at a pre-incubation concentration of Cu2O@TPPO of 2.5 μg / mL, the intracellular red fluorescence was slightly enhanced compared to the control group. When the pre-incubation concentration reached 5.0 μg / mL, the fluorescence intensity was five times that of the control group, and at an incubation concentration of 10.0 μg / mL, the fluorescence intensity was nearly six times that of the control group. These results indicate that Cu2O@TPPO can effectively induce the generation of ROS in the mitochondria of tumor cells.
[0047] 11. Cu2O@TPPO Leads to Decreased Mitochondrial Membrane Potential in A549 Cells. Dysregulation of ROS production and ROS restriction pathways can lead to cancer, but excessive intracellular ROS can also cause mitochondrial damage in tumor cells, resulting in a decrease in mitochondrial membrane potential (ΔΨm) and exerting an anti-tumor effect. To investigate the effect of Cu2O@TPPO on mitochondrial membrane potential, we used the JC-1 fluorescent probe to detect the mitochondrial membrane potential level of A549 cells. JC-1, as a cationic lipid fluorescent probe, showed a significant correlation between its fluorescence emission characteristics and mitochondrial transmembrane potential: under high membrane potential, JC-1 molecules aggregate to form JC-1 aggregates, exhibiting red fluorescence emission; while under membrane potential depolarization, the probe exists in monomeric form, mainly emitting green fluorescence. Fluorescence microscopy observations showed that red fluorescence was significantly weakened and green fluorescence was significantly enhanced in cells treated with Cu2O@TPPO. Figure 15 a). The results of flow cytometry quantitative analysis were consistent with microscopic observations. Figure 15 (b) This further confirmed the significant decrease in mitochondrial membrane potential in the drug-treated cells. These results indicate that Cu2O@TPPO may induce a decrease in mitochondrial membrane potential in A549 cells by generating large amounts of ROS, thereby potentially mediating its antitumor effect through the mitochondrial pathway.
[0048] 12. Cu2O@TPPO Induces Apoptosis in A549 Cells. Programmed apoptosis in cells is mainly carried out through two signaling pathways: the death receptor pathway and the mitochondrial pathway. The death receptor pathway is initiated by the binding of ligands to the FAS receptor on the cell surface, while the mitochondrial pathway is closely related to changes in mitochondrial transmembrane potential. When mitochondrial depolarization occurs, the expression of the pro-apoptotic protein Bax is upregulated, leading to increased mitochondrial outer membrane permeability, which in turn promotes the release of pro-apoptotic factors such as CytC (Cytochrome C) and apoptosis-inducing factor AIFM1 (Apoptosis-Inducing Factor 1) from the mitochondrial intermembrane space into the cytoplasm. Among them, CytC can activate Caspase-3, ultimately inducing apoptosis. Based on the experimental results that Cu2O@TPPO can significantly reduce mitochondrial membrane potential, we further used the annexin V / PI double staining method to analyze the apoptosis of A549 cells after Cu2O@TPPO treatment. Figure 16 As shown, drug intervention significantly increased the early and late apoptosis rates of A549 cells, and this pro-apoptotic effect was dose-dependent. Western blot analysis revealed significantly increased activation of Caspase-8, a key effector molecule in the death receptor pathway, and significantly increased expression levels of Bax, a mitochondrial pathway-related protein. Figure 16 b). Notably, the expression of the activated fragment of Caspase-3, a key protease for apoptosis, was also significantly increased. Figure 16 b). This molecular-level evidence confirms that Cu2O@TPPO can exert its anti-tumor activity by activating mitochondrial-dependent apoptosis pathway and death receptor pathway to induce programmed cell death in tumor cells.
[0049] 13. Cu2O@TPPO Induces Cell Cycle Arrest in S Phase of A549 Cells. When cellular DNA damage is mild, cells initiate repair mechanisms and induce cell cycle arrest, providing time for DNA repair. However, when DNA damage is severe and irreparable, cells initiate apoptosis or other forms of programmed cell death. In previous studies, we have demonstrated that Cu2O@TPPO can cause severe DNA damage in A549 cells. To further investigate its effect on the cell cycle, we used a cell cycle assay kit to analyze the cell cycle distribution after treatment with different concentrations of Cu2O@TPPO. Figure 17 As shown in figure a, cell cycle analysis revealed that Cu2O@TPPO treatment significantly increased the proportion of cells in S phase compared to the control group. This phenomenon suggests that Cu2O@TPPO may induce cell cycle checkpoint activation through DNA damage, thereby triggering S phase arrest and ultimately inhibiting tumor cell proliferation.
[0050] To further verify the occurrence of cell cycle arrest, we used Western blot to detect proteins related to DNA damage and cell cycle arrest. The results showed that after 12 hours of drug treatment, the expression of p53 and its downstream p21 proteins was significantly increased compared to the control group, while the expression of cyclin D was significantly decreased. Figure 17 b). These findings suggest that Cu2O@TPPO can activate the p53-p21 signaling pathway by inducing DNA damage, thereby causing cell cycle arrest and ultimately inhibiting tumor cell proliferation.
[0051] 14. Cu2O@TPPO Induces Copper Death in A549 Cells. To verify whether Cu2O@TPPO can reduce intracellular GSH levels, we used a reduced glutathione assay kit to quantitatively analyze GSH levels in the drug-treated and control groups. The results showed that, compared with the control group, the intracellular GSH level in the Cu2O@TPPO treatment group decreased in a dose-dependent manner, with a decrease exceeding 50% at a concentration of 10.0 μg / mL. Figure 18 b). This discovery not only reveals the characteristic of Cu2O@TPPO enhancing the effectiveness of copper ions by consuming GSH, but also provides key experimental evidence for its anti-tumor effect through the copper death pathway.
[0052] To systematically verify whether Cu2O@TPPO can exert antitumor effects through the copper death pathway, we used Western blot to detect the protein expression levels of FDX1 and LIAS in A549 cells. The results showed that after treatment with Cu2O@TPPO, the protein expression of both FDX1 and LIAS in A549 cells exhibited a significant downregulation trend. Figure 18 c), and the difference was statistically significant. Figure 18 (d, e). This change in molecular expression profile, which closely matches the characteristics of copper death, directly confirms that Cu2O@TPPO can activate the copper death pathway and provides new experimental evidence for tumor treatment strategies based on the mechanism of copper death.
[0053] During copper death, cells undergo typical morphological changes such as mitochondrial membrane rupture, membrane shrinkage, and cristae reduction. We observed the morphology of mitochondria in tumor cells under the action of Cu2O@TPPO using transmission electron microscopy. The results showed that under the action of Cu2O@TPPO, there was significant rupture of the inner mitochondrial membrane, disappearance of the mitochondrial cristae, and swelling and vacuolation of mitochondria. Figure 18 f).
[0054] 15. Cu2O@TPPO exhibits in vivo antitumor activity and biosafety. To comprehensively evaluate the antitumor efficacy of Cu2O@TPPO, we established an A549 xenograft tumor model for in vivo pharmacodynamic studies. The results showed that after seven treatments, the tumor volume in the control group mice continued to increase. Although the cisplatin treatment group showed some tumor inhibition, the tumor volume continued to increase. In contrast, the Cu2O@TPPO treatment group showed a significant tumor growth inhibition effect, with the tumor volume remaining stable throughout the treatment period without significant increase. Figure 19 a, b). Furthermore, the average tumor mass in the Cu2O@TPPO treatment group was reduced by approximately 50% compared to the control group, and its tumor-suppressing effect was significantly superior to that of the equivalent dose cisplatin treatment group ( Figure 19 c).
[0055] Western blot analysis revealed the in vivo antitumor mechanism of Cu2O@TPPO. Quantitative results showed that, compared with the control group, the expression of pro-apoptotic proteins in the tumor tissues of mice treated with Cu2O@TPPO was significantly upregulated: Bax protein expression increased to 3.5 times that of the control group, and the expression levels of cleaved-Caspase-3 and cleaved-Caspase-8 increased by approximately 1.5 times. Simultaneously, the expression levels of key cell cycle regulatory proteins p53 and p21 were 1.3 times and 2.0 times, respectively, compared with the control group. Figure 20This indicates that Cu2O@TPPO may induce cell cycle arrest by activating the p53-p21 signaling pathway. Notably, the trends in these protein expression changes are highly consistent with previous cell experiments, further confirming that Cu2O@TPPO exerts its anti-tumor effects through a dual regulatory mechanism of apoptosis and cell cycle arrest.
[0056] To systematically evaluate the in vivo safety characteristics of Cu2O@TPPO, we conducted a systematic toxicological assessment experiment. Histopathological analysis of the major organs (heart, liver, spleen, lung, and kidney) of the experimental animals was performed using hematoxylin and eosin (H&E) staining. The results showed that, compared with the control group, the tissue structure of each organ in the Cu2O@TPPO treatment group was intact, the cells were arranged in an orderly manner, and no obvious inflammatory infiltration, necrosis, or fibrosis was observed. Figure 21 This initially confirmed that the nanoparticles possess good tissue compatibility. We further evaluated their systemic toxicity through blood biochemistry analysis. The results showed that liver function indicators (including total bilirubin, albumin, alanine aminotransferase, and aspartate aminotransferase) and kidney function indicators (blood urea nitrogen, creatinine, and uric acid) in mice treated with Cu2O@TPPO were all within the normal reference range, and there were no statistically significant differences compared to the control group. Figure 22 (ag). Additionally, in organ mass analysis, the mass indices of major organs such as the heart, liver, spleen, lungs, and kidneys in the Cu2O@TPPO treatment group were comparable to those in the control group, while the cisplatin treatment group showed a significant decrease in liver and spleen mass. Figure 23 Based on comprehensive histopathological, blood biochemical, and organ quality analysis results, we confirmed that Cu2O@TPPO did not cause significant liver or kidney dysfunction or metabolic disorders at the experimental dose, demonstrating good biocompatibility. This finding provides important safety evidence for its further clinical application.
Claims
1. A nanocomposite Cu2O@TPPO, characterized in that, The preparation method of the Cu2O@TPPO nanocomposite is as follows: Commercial Stryker reagent ((Ph3P)6[CuH]6 cluster, purity 98%) is directly used as a copper precursor and placed in a glass container. It is left to stand for 24 hours under normal atmospheric pressure to allow spontaneous surface hydrolysis and in-situ oxidation of the triphenylphosphine oxide ligand. The entire process requires no additional solvents, ligand additives, heating, or cooling. After the reaction, the obtained Cu2O@TPPO nanoparticles are dispersed in dichloromethane (DCM) and purified by centrifugation at 8000 rpm for 10 minutes. The resulting precipitate is washed with DCM 3-5 times to thoroughly remove residual unreacted Stryker reagent and free phosphine byproducts. The purified Cu2O@TPPO nanoparticles are finally dried naturally under vacuum for 48 hours and stored in a dry, light-proof container for subsequent characterization and performance testing.
2. The application of the Cu2O@TPPO nanocomposite according to claim 1 in the preparation of antitumor drugs.
